Answers are grounded in this paper and cite their sources.
Clinically important hematological toxicity is uncommon with carbamazepine (CBZ). Only 20 patients with CBZ‐associated aplastic anemia have been reported since 1964. Leukopenia and thrombocytopenia occur in about 2% of patients. Based on the available data on hematological complications of CBZ, we question the justification for expensive, excessive laboratory monitoring.
No takes yet. Share an insight, caveat, or question.
Hart et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: